Astrana Health, Inc.
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Unregistered Sales of Equity Securities
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
In December 2022, Astrana’s Board of Directors approved a share repurchase plan authorizing the Company to repurchase up to $50.0 million of its shares of common stock on the open market and through privately negotiated transactions. This share repurchase plan does not have an expiration date. The Board may suspend or discontinue the repurchase plan at any time. This repurchase plan does not obligate the Company to make additional repurchases at any specific time or in any specific situation. During the three months ended September 30, 2025, no shares were repurchased under the Company’s share repurchase plan. As of September 30, 2025, $40.5 million remained available for repurchase under the repurchase plan.
The following table provides information about purchases made by the Company of shares of the Company’s common stock during the three months ended September 30, 2025.
| Period | Total Numberof SharesPurchased(1) | Average PricePaid perShare | Total Number ofSharesPurchased asPart of PubliclyAnnounced Plansor Programs | Approximate DollarValue of Shares thatMay Yet BePurchased Under thePlans or Programs(in thousands) |
|---|---|---|---|---|
| July 1, 2025 to July 31, 2025 | 10,177 | $25.19 | — | $40,461 |
| August 1, 2025 to August 31, 2025 | 533 | $29.63 | — | $40,461 |
| September 1, 2025 to September 30, 2025(2) | 41,099 | $28.87 | — | $40,461 |
| Total | 51,809 | $28.15 | — | $40,461 |
(1)
Shares were repurchased to satisfy tax withholding obligations due upon the vesting of restricted stock awards held by certain employees, except as otherwise disclosed in these footnotes. We did not pay cash to repurchase these shares, nor were these repurchases part of a publicly announced plan or program.
(2)
Includes 33,214 shares of common stock repurchased from two members of the Board of Directors during September 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.